ArticleFrontiers in medicine2025
Association of chronic Chagas cardiomyopathy stages with obstructive sleep apnea and excessive daytime sleepiness: a cross-sectional study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chagas disease (CD) remains a significant cause of morbidity and mortality in Latin America. Chronic Chagas cardiomyopathy (CCC) is the most severe clinical form. Obstructive sleep apnea (OSA), a highly prevalent sleep-related breathing disorder, is associated with adverse cardiovascular and metabolic outcomes, yet its clinical relevance in CD remains poorly understood. This study aimed to examine the association between the stages of CCC with the OSA risk and excessive daytime sleepiness (EDS) in patients with CD. Methods: This cross-sectional observational study included patients with chronic CD. OSA risk was assessed using the STOP-BANG questionnaire; EDS was measured by the Epworth Sleepiness Scale. CCC staging followed the 2nd Brazilian Consensus on CD. Categorical variables were compared using Pearson's chi-square test and continuous variables with ANOVA. Logistic regression models were fitted to explore associations between CCC stages with OSA risk and EDS. Results: A total of 133 patients (35.3% men; mean age 67.1 years) were included. Of these, 34.6% had no CCC, 49.6% were CCC stages A/B1, and 15.8% were stages B2/C. Of the 130 participants who completed the STOP-Bang questionnaire, 19.2% were at low risk for OSA (score ≤2), while 80.8% were at intermediate or high risk (score >2). EDS (Epworth Sleepiness Scale >10) was identified in 19.6% of participants. No significant associations were found between CCC stages with either OSA risk or EDS. Conclusion: Despite a high prevalence of OSA risk among patients with CD, no association was observed between CCC severity and OSA risk or EDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.